Ahmed Koriesh/LinkedIn
Mar 27, 2026, 17:19
Ahmed Koriesh: Would You Start DAPT If the Patient Presents After 24 Hours?
Ahmed Koriesh, Director of Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”Would you start DAPT if the patient presents after 24 hours?
Yes — why not.
The key concept
- Stroke recurrence risk is front-loaded.
- Highest risk in the first 3–7 days
- Then declines significantly
When you look at recurrence curves:
Steep early rise to gradual flattening
Why this matters
- Early phase equals unstable plaque, high embolic risk
- This is where DAPT has the greatest impact
Practical take
- <24h: ideal (trial-based)
- 24h – several days: still meaningful benefit
- Approxmately 1 week: diminishing returns
There is no sharp cutoff — it’s a gradient, not a binary window
What about the Trials?
- Trials (CHANCE/POINT) used ≤24h to maximize efficacy
- But biology doesn’t stop at 24h
- Risk – and potential benefit – persists beyond that
Bottom line
If patient present with minor stroke after 24h, still within few days, would still benefit from DAPT to reduce recurrence, specially in high risk patients.”

Stay updated with Hemostasis Today.
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children